Adage Capital Partners Gp, L.L.C. Amgen Inc Transaction History

Adage Capital Partners Gp, L.L.C.

$54.9 Billion
Q4 2024

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Amgen Inc stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 304,727 shares of AMGN stock, worth $97.2 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

304,727

Previous 601,662 49.35%

Holding current value

$97.2 Million

Previous $194 Million 59.03%

% of portfolio

0.14%

Previous 0.35%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$258.78 - $328.31 $76.8 Million - $97.5 Million	-296,935 Reduced 49.35%	304,727 $79.4 Million
Q3 2024 Nov 14, 2024	BUY	$309.38 - $337.38 $7.23 Million - $7.88 Million	23,366 Added 4.04%	601,662 $194 Million
Q2 2024 Aug 14, 2024	BUY	$262.75 - $319.31 $42 Million - $51 Million	159,729 Added 38.16%	578,296 $181 Million
Q1 2024 May 15, 2024	SELL	$268.87 - $324.56 $150 Million - $181 Million	-558,017 Reduced 57.14%	418,567 $119 Million
Q4 2023 Feb 14, 2024	BUY	$255.7 - $288.46 $65 Million - $73.4 Million	254,334 Added 35.21%	976,584 $281 Million
Q3 2023 Nov 14, 2023	BUY	$218.65 - $271.46 $78.3 Million - $97.2 Million	358,137 Added 98.36%	722,250 $194 Million
Q2 2023 Aug 14, 2023	BUY	$214.27 - $253.37 $1.79 Million - $2.12 Million	8,357 Added 2.35%	364,113 $80.8 Million
Q1 2023 May 15, 2023	SELL	$225.79 - $275.2 $3.95 Million - $4.81 Million	-17,484 Reduced 4.68%	355,756 $86 Million
Q4 2022 Feb 14, 2023	BUY	$229.03 - $291.01 $85.5 Million - $109 Million	373,240 New	373,240 $98 Million
Q4 2021 Feb 14, 2022	SELL	$198.88 - $227.6 $33.7 Million - $38.5 Million	-169,238 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$212.27 - $248.7 $27.8 Million - $32.6 Million	131,200 Added 344.92%	169,238 $36 Million
Q2 2021 Aug 16, 2021	SELL	$233.58 - $259.14 $94.1 Million - $104 Million	-403,000 Reduced 91.38%	38,038 $9.27 Million
Q1 2021 May 17, 2021	SELL	$221.91 - $258.6 $13.8 Million - $16.1 Million	-62,100 Reduced 12.34%	441,038 $110 Million
Q4 2020 Feb 16, 2021	SELL	$216.38 - $257.67 $25.5 Million - $30.4 Million	-118,029 Reduced 19.0%	503,138 $116 Million
Q3 2020 Nov 16, 2020	SELL	$234.65 - $260.95 $49.8 Million - $55.4 Million	-212,405 Reduced 25.48%	621,167 $158 Million
Q2 2020 Aug 14, 2020	BUY	$197.81 - $242.74 $42.3 Million - $51.9 Million	213,700 Added 34.47%	833,572 $197 Million
Q1 2020 May 15, 2020	BUY	$182.24 - $241.7 $38.1 Million - $50.6 Million	209,325 Added 50.99%	619,872 $126 Million
Q4 2019 Feb 14, 2020	BUY	$189.21 - $243.2 $7.25 Million - $9.31 Million	38,300 Added 10.29%	410,547 $99 Million
Q3 2019 Nov 14, 2019	BUY	$174.11 - $208.62 $51.1 Million - $61.2 Million	293,300 Added 371.52%	372,247 $72 Million
Q2 2019 Aug 14, 2019	SELL	$166.7 - $195.41 $22.4 Million - $26.2 Million	-134,300 Reduced 62.98%	78,947 $14.5 Million
Q1 2019 May 15, 2019	SELL	$180.87 - $203.88 $36.1 Million - $40.7 Million	-199,808 Reduced 48.37%	213,247 $40.5 Million
Q4 2018 Feb 14, 2019	SELL	$178.4 - $208.25 $7.08 Million - $8.27 Million	-39,700 Reduced 8.77%	413,055 $80.4 Million
Q3 2018 Nov 14, 2018	SELL	$185.29 - $208.89 $52.3 Million - $59 Million	-282,300 Reduced 38.41%	452,755 $93.9 Million
Q2 2018 Aug 14, 2018	BUY	$166.05 - $186.51 $26.4 Million - $29.7 Million	159,148 Added 27.63%	735,055 $136 Million
Q1 2018 May 15, 2018	SELL	$169.43 - $198.0 $59.9 Million - $70 Million	-353,502 Reduced 38.04%	575,907 $98.2 Million
Q4 2017 Feb 14, 2018	BUY	$168.79 - $188.59 $19.1 Million - $21.4 Million	113,300 Added 13.88%	929,409 $162 Million
Q3 2017 Nov 14, 2017	BUY	$167.29 - $191.0 $137 Million - $156 Million	816,109	816,109 $152 Million

Others Institutions Holding AMGN

# of Institutions

3,179

Shares Held

419M

Call Options Held

8.25M

Put Options Held

6.39M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $171B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Amgen Inc Transaction History